{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:29:52Z","timestamp":1791685792450,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC3601800"],"award-info":[{"award-number":["2022YFC3601800"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.intimp.2026.116775","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T16:47:57Z","timestamp":1777999677000},"page":"116775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Epalrestat repurposing for psoriasis: Targeting AKR1B10 to modulate the metabolic-immune axis via restoring retinol metabolism and suppressing IL-17 signaling"],"prefix":"10.1016","volume":"181","author":[{"given":"Lisha","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10281","key":"10.1016\/j.intimp.2026.116775_bb0005","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"19","key":"10.1016\/j.intimp.2026.116775_bb0010","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.intimp.2026.116775_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116775_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115429","article-title":"Advancing insights into psoriasis: from pathogenesis to current and emerging therapies","volume":"165","author":"Gon\u00e7alves","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.116775_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122991","article-title":"Advances in psoriasis research: from pathogenesis to therapeutics","volume":"355","author":"Sugumaran","year":"2024","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.116775_bb0030","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10275","key":"10.1016\/j.intimp.2026.116775_bb0035","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"Pt 1","key":"10.1016\/j.intimp.2026.116775_bb0040","article-title":"Current therapeutic overview and future perspectives regarding the treatment of psoriasis","volume":"143","author":"Ferrara","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116775_bb0045","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","article-title":"Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis","volume":"84","author":"Thomas","year":"2024","journal-title":"Drugs"},{"issue":"Pt 3","key":"10.1016\/j.intimp.2026.116775_bb0050","article-title":"From manifestations to innovations: a deep dive into psoriasis, its clinical diversity, conventional treatments, and emerging therapeutic paradigms","volume":"143","author":"Garg","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116775_bb0055","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116775_bb0060","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/jdv.18044","article-title":"Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis","volume":"36","author":"Wu","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116775_bb0065","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116775_bb0070","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40257-024-00857-0","article-title":"Managing the patient with psoriasis and metabolic comorbidities","volume":"25","author":"Bellinato","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2026.116775_bb0075","first-page":"1","article-title":"Type 2 diabetes and psoriasis: links and risks","volume":"9","author":"Holm","year":"2019","journal-title":"Psoriasis (Auckland, N.Z.)"},{"issue":"13","key":"10.1016\/j.intimp.2026.116775_bb0080","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","article-title":"Cardiovascular risk in patients with psoriasis: JACC review topic of the week","volume":"77","author":"Garshick","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116775_bb0085","doi-asserted-by":"crossref","DOI":"10.1007\/s12016-025-09089-4","article-title":"Systemic psoriasis: from molecular mechanisms to global management strategies","volume":"68","author":"Prema","year":"2025","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116775_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11060332","article-title":"The role of AKR1B10 in physiology and pathophysiology","volume":"11","author":"Endo","year":"2021","journal-title":"Metabolites"},{"issue":"4","key":"10.1016\/j.intimp.2026.116775_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166319","article-title":"Role of AKR1B10 and AKR1B8 in the pathogenesis of non-alcoholic steatohepatitis (NASH) in mouse","volume":"1868","author":"Rajak","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"6","key":"10.1016\/j.intimp.2026.116775_bb0100","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00535-019-01551-3","article-title":"Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis","volume":"54","author":"Kanno","year":"2019","journal-title":"J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116775_bb0105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12192-013-0455-6","article-title":"AKR1B10 is induced by hyperglycaemia and lipopolysaccharide in patients with diabetic nephropathy","volume":"19","author":"Shaw","year":"2014","journal-title":"Cell Stress Chaperones"},{"issue":"17","key":"10.1016\/j.intimp.2026.116775_bb0110","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1158\/1078-0432.CCR-23-3980","article-title":"Targeting AKR1B10 by drug repurposing with Epalrestat overcomes chemoresistance in non-small cell lung cancer patient-derived tumor organoids","volume":"30","author":"Suvilesh","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116775_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70561","article-title":"AARS1-mediated AKR1B10 lactylation stabilizes an aerobic glycolysis-positive feedback loop to drive Lenvatinib resistance in hepatocellular carcinoma","volume":"16","author":"Liu","year":"2026","journal-title":"Clin. Transl. Med."},{"issue":"10","key":"10.1016\/j.intimp.2026.116775_bb0120","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s00535-023-02011-9","article-title":"Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma","volume":"58","author":"Xie","year":"2023","journal-title":"J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116775_bb0125","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1021\/acs.jmedchem.4c01116","article-title":"In search for inhibitors of human Aldo-keto reductase 1B10 (AKR1B10) as novel agents to fight cancer and chemoresistance: current state-of-the-art and prospects","volume":"68","author":"Maccari","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2026.116775_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112812","article-title":"Metabolomics and molecular dynamics unveil the therapeutic potential of Epalrestat in diabetic nephropathy","volume":"140","author":"Song","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.116775_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115106","article-title":"Epalrestat, an aldose reductase inhibitor, mitigates Doxorubicin-induced cardiotoxicity by inhibiting glycometabolism","volume":"162","author":"Zhu","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116775_bb0140","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13578-021-00677-3","article-title":"AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K\/AKT\/NF-\u03baB signaling pathway","volume":"11","author":"Qu","year":"2021","journal-title":"Cell Biosci."},{"issue":"11","key":"10.1016\/j.intimp.2026.116775_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100303","article-title":"AKR1B10 is a new sensitive and specific marker for fumarate hydratase-deficient renal cell carcinoma","volume":"36","author":"Zheng","year":"2023","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.intimp.2026.116775_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110145","article-title":"Pivotal role of AKR1B1 in pathogenesis of colitis associated colorectal carcinogenesis","volume":"119","author":"Syamprasad","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116775_bb0155","first-page":"5836","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"Journal of immunology (Baltimore, Md.\u202f: 1950)"},{"issue":"5","key":"10.1016\/j.intimp.2026.116775_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.70078","article-title":"Fastp 1.0: an ultra-fast all-round tool for FASTQ data quality control and preprocessing","volume":"4","author":"Chen","year":"2025","journal-title":"iMeta"},{"issue":"4","key":"10.1016\/j.intimp.2026.116775_bb0165","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.3317","article-title":"HISAT: a fast spliced aligner with low memory requirements","volume":"12","author":"Kim","year":"2015","journal-title":"Nat. Methods"},{"issue":"2","key":"10.1016\/j.intimp.2026.116775_bb0170","first-page":"166","article-title":"HTSeq--a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinf. (Oxf.)"},{"issue":"D1","key":"10.1016\/j.intimp.2026.116775_bb0175","doi-asserted-by":"crossref","first-page":"D330","DOI":"10.1093\/nar\/gky1055","article-title":"The gene ontology resource: 20 years and still GOing strong","volume":"47","author":"The Gene Ontology Consortium","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"10.1016\/j.intimp.2026.116775_bb0180","doi-asserted-by":"crossref","first-page":"D587","DOI":"10.1093\/nar\/gkac963","article-title":"KEGG for taxonomy-based analysis of pathways and genomes","volume":"51","author":"Kanehisa","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"43","key":"10.1016\/j.intimp.2026.116775_bb0185","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"D1","key":"10.1016\/j.intimp.2026.116775_bb0190","doi-asserted-by":"crossref","first-page":"D730","DOI":"10.1093\/nar\/gkae1113","article-title":"The STRING database in 2025: protein networks with directionality of regulation","volume":"53","author":"Szklarczyk","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.116775_bb0195","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.116775_bb0200","article-title":"MiR-193b-3p-ERBB4 axis regulates psoriasis pathogenesis via modulating cellular proliferation and inflammatory-mediator production of keratinocytes","volume":"12","author":"Huang","year":"2021","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.intimp.2026.116775_bb0205","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.intimp.2026.116775_bb0210","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cbi.2014.09.024","article-title":"The aldo-keto reductases (AKRs): overview","volume":"234","author":"Penning","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.intimp.2026.116775_bb0215","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev.pharmtox.47.120505.105337","article-title":"Aldo-keto reductases and bioactivation\/detoxication","volume":"47","author":"Jin","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116775_bb0220","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.jid.2016.03.022","article-title":"The aldo-keto reductase AKR1B10 is up-regulated in keloid epidermis, implicating retinoic acid pathway dysregulation in the pathogenesis of keloid disease","volume":"136","author":"Jumper","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"1\u20133","key":"10.1016\/j.intimp.2026.116775_bb0225","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cbi.2008.10.027","article-title":"Aldo-keto reductases from the AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels","volume":"178","author":"Ruiz","year":"2009","journal-title":"Chem. Biol. Interact."},{"issue":"52","key":"10.1016\/j.intimp.2026.116775_bb0230","doi-asserted-by":"crossref","first-page":"20764","DOI":"10.1073\/pnas.0705659105","article-title":"Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10","volume":"104","author":"Gallego","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.intimp.2026.116775_bb0235","doi-asserted-by":"crossref","first-page":"756","DOI":"10.7150\/ijbs.52927","article-title":"AKR1B10 confers resistance to radiotherapy via FFA\/TLR4\/NF-\u03baB axis in nasopharyngeal carcinoma","volume":"17","author":"Liu","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.intimp.2026.116775_bib306","doi-asserted-by":"crossref","first-page":"8717369","DOI":"10.1155\/2017\/8717369","article-title":"Combined Transcriptomic Analysis Revealed AKR1B10 Played an Important Role in Psoriasis through the Dysregulated Lipid Pathway and Overproliferation of Keratinocyte","volume":"2017","author":"Gao","year":"2017","journal-title":"Biomed. Res. Int."},{"issue":"5","key":"10.1016\/j.intimp.2026.116775_bib307","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.3390\/ijms24054556","article-title":"Psoriatic Resolved Skin Epidermal Keratinocytes Retain Disease-Residual Transcriptomic and Epigenomic Profiles","volume":"24","author":"Ghaffarinia","year":"2023","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.intimp.2026.116775_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2026.116194","article-title":"Limosilactobacillus reuteri alleviates psoriasis via aryl hydrocarbon receptor-mediated regulation of Interkeukin-17A","volume":"172","author":"Hong","year":"2026","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.116775_bb0245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.941071","article-title":"Dendritic cells and macrophages in the pathogenesis of psoriasis","volume":"13","author":"Kamata","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116775_bb0250","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12986-019-0423-y","article-title":"Retinol and vitamin a metabolites accumulate through RBP4 and STRA6 changes in a psoriasis murine model","volume":"17","author":"Wang","year":"2020","journal-title":"Nutrition & metabolism"},{"issue":"5 Suppl","key":"10.1016\/j.intimp.2026.116775_bb0255","doi-asserted-by":"crossref","first-page":"47S","DOI":"10.1111\/1523-1747.ep12505769","article-title":"Metabolism of natural retinoids in psoriatic epidermis","volume":"95","author":"Siegenthaler","year":"1990","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2026.116775_bb0260","article-title":"Liquiritin exerts psoriasis therapy and prevention by regulating the YY1\/RBP3 axis","volume":"134","author":"Deng","year":"2024","journal-title":"Phytomed. Int. J. Phytother. Phytopharm."},{"issue":"2","key":"10.1016\/j.intimp.2026.116775_bb0265","first-page":"239","article-title":"Adipokines and psoriasis: the obesity link","volume":"179","author":"Kirby","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116775_bb0270","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/bjd\/ljae199","article-title":"Insulin resistance and psoriasis","volume":"191","author":"Parraga","year":"2024","journal-title":"Br. J. Dermatol."},{"issue":"19","key":"10.1016\/j.intimp.2026.116775_bb0275","doi-asserted-by":"crossref","first-page":"11429","DOI":"10.1074\/jbc.273.19.11429","article-title":"Identification and characterization of a novel human aldose reductase-like gene","volume":"273","author":"Cao","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.intimp.2026.116775_bb0280","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0149-2918(95)80111-1","article-title":"Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus","volume":"17","author":"Uchida","year":"1995","journal-title":"Clin. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2026.116775_bb0285","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1592\/phco.28.5.646","article-title":"Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy","volume":"28","author":"Ramirez","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.intimp.2026.116775_bb0290","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41598-025-30398-3","article-title":"ADIPOQ regulates lipid metabolism by activating AMPK\/CPT-1 pathway to attenuate the proliferation of psoriasis lesions","volume":"16","author":"Xing","year":"2025","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2026.116775_bb0295","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bjd.16560","article-title":"Methotrexate restores the function of peripheral blood regulatory T cells in psoriasis vulgaris via the CD73\/AMPK\/mTOR pathway","volume":"179","author":"Yan","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2026.116775_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02786","article-title":"Epidermal mTORC1 signaling contributes to the pathogenesis of psoriasis and could serve as a therapeutic target","volume":"9","author":"Buerger","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116775_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1075804","article-title":"Dual targeting of mTOR\/IL-17A and autophagy by fisetin alleviates psoriasis-like skin inflammation","volume":"13","author":"Roy","year":"2023","journal-title":"Front. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926006211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926006211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:55:10Z","timestamp":1783155310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926006211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":63,"alternative-id":["S1567576926006211"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116775","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epalrestat repurposing for psoriasis: Targeting AKR1B10 to modulate the metabolic-immune axis via restoring retinol metabolism and suppressing IL-17 signaling","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116775"}}